Pipeline 2018-06-04T14:07:18+00:00

Product Pipeline

EyePoint has developed three FDA-approved products utilizing our proprietary DurasertTM Technology.

We are utilizing our Durasert bioerodible technology platform in collaboration with other pharmaceutical companies to develop new sustained-release products to treat retinal diseases and other ocular conditions.

We are expanding our focus beyond eye diseases to leverage our Durasert Technology for the treatment of musculoskeletal conditions.

Dexycu (dexamethasone intraocular suspension) 9%Approved
Durasert three-year treatment
Potential Indication: posterior segment uveitis
Durasert shorter duration treatment
Potential Indication: posterior segment uveitis
Durasert TKI
Potential Indication: Wet AMD
Potential Indication: Knee OA
Phase 1
Front of the eye diseasePreclinical
Back of the eye diseasePreclinical

Dexycu (dexamethasone injectable suspension) 9%

click here for full Prescribing Information

Please complete the form below to receive information on the availability of Dexycu.

DurasertTM Three-year for Posterior Uveitis

Potential Indication: posterior segment uveitis

EyePoint filed an NDA in January 2018 and received a target PDUFA date of November 5, 2018 from the FDA. EyePoint has out-licensed the rights for Europe, Middle East and Africa (EMEA) to Alimera Sciences as part of a broader amendment to its current licensing and collaboration agreement for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg.

DurasertTM Shorter Duration for Posterior Uveitis

Potential Indication: posterior segment uveitis

EyePoint is currently developing a shorter-duration sustained-release fluocinolone acetonide product in the proven DurasertTM Technology.

DurasertTM Bioerodible TKI

Potential Indication: Wet AMD

EyePoint is focused on developing a sustained-release bioerodible device containing a tyrosine kinase inhibitor (TKI) to assess its potential to treat wet AMD. In-vitro release profiles have been assessed for several TKIs. EyePoint is actively seeking partners interested in advancing the program to clinical-stage development.

DurasertTM for Knee Osteoarthritis (OA)

Potential Indication: Knee OA

EyePoint is working with the Hospital for Special Surgery (HSS) in New York City on a titanium screw drug implant containing the corticosteroid dexamethasone. The screw implant utilizes the DurasertTM Technology and is designed to release a low dose of dexamethasone. This investigator-initiated study is being conducted by HSS. A total of 6 patients have been enrolled as of the 2nd quarter of 2017 and will be followed for a period 6 months.